SEC Company Response from Tempest Therapeutics, Inc. (TPST) (CIK 0001544227) (TPST) — Aug 27, 2026
Tempest Therapeutics, Inc. (TPST) (CIK 0001544227)
Date: Aug. 27, 2026 · CIK: 0001544227 · Accession: 0001193125-26-371259
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-298498
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Attention: Alan Campbell Tempest Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1 (the “Registration Statement”) Filed August 21, 2026 File No. 333-298498
Dear Mr. Campbell:
The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of effectiveness of the Registration Statement so that such Registration Statement will become effective as of 4:00 p.m. on August 31, 2026, or as soon thereafter as practicable.
[Signature page follows]
Very truly yours,
Tempest Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane, California, 94005 August 27, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Alan Campbell RE: Tempest Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1 (the “Registration Statement”) Filed August 21, 2026 File No. 333-298498 Dear Mr. Campbell: The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of effectiveness of the Registration Statement so that such Registration Statement will become effective as of 4:00 p.m. on August 31, 2026, or as soon thereafter as practicable. [Signature page follows] Very truly yours, Tempest Therapeutics, Inc. By: /s/ Matthew Angel Name: Matthew Angel Title: President and Chief Executive Officer